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Mass spectrometryBackground: Intrauterine growth restriction (IUGR) is associated with short- and long-term metabolic
consequences which are possibly dictated by in utero programming together with environmental and
dietetic manipulation after birth. Early detection of metabolic derangements in these babies through
metabolomics approach will help recognition of cases in need for further follow-up and can help future
development of therapeutic and preventive strategies for the late consequences.
Objective: To compare amino acids and acyl carnitine levels in neonates with IUGR to normal birth
weight controls; as a part of metabolic profiling.
Methods: Cord blood samples were collected at birth from 40 small-for-gestational-age (SGA) neonates
and 20 normal birth weight gestational age-matched neonates, for quantification of amino acids and acyl-
carnitines using Ultra Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS).
Results: Significantly elevated acylcarnitine levels especially C18-OH and C16-OH were found in IUGR
neonates vs. controls (p < 0.001). Specific amino acids that were significantly elevated in IUGR neonates
included Histidine, Methionine, Arginine, Aspartic, Valine, Alanine, Leucine, Isoleucine, Glutamic acid,
Tyrosine, Ornithine, Phenylalanine, and lastly citrulline. These derangements were recognized to be sim-
ilar to those found in different disorders.
Conclusion: We conclude that IUGR neonates have unique metabolic derangements detectable by UPLC-
MS at birth with similarities to derangements found in certain disorders. These babies should be closely
followed up for early detection of the metabolic consequences of IUGR.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Intrauterine growth restriction (IUGR) or small-for-gestational-
age (SGA) is defined as birth weight or birth crown-heel length of
less than 10th percentile for gestational age. Both terms are used
interchangeably [1].Prevalence of IUGR in the general population worldwide was
estimated to be 7–15%, while in developing countries – including
Egypt – it reaches up to 30% and constitutes 50–60% of low birth
weight neonates (with birth weight of less than 2500 g) [2,3].
There is growing evidence that IUGR is strongly associated with
several short- and long-term complications including, for instance,
cognitive and psycho-physical developmental disorders during
infancy and the metabolic syndrome during adulthood [4,5]. These
consequences are probably related to ‘‘Perinatal Programming” and
strongly correlated to postnatal dietetic rehabilitation and fast
catch-up growth [5,6].
Biomarkers in medicine, particularly in Neonatology, are crucial
for defining diagnosis and predicting prognosis of many diseases
[7].
Certain biomarkers were previously identified and speculated
as being correlated with IUGR such as maternal levels of
endothelin-1 and leptin during pregnancy and urinary protein
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were useful as early predictors for later development of insulin
resistance and type 2 diabetes mellitus [10].
However, through the last 2 decades, a new generation of
biomarkers has been extensively studied; the metabolites compris-
ing the metabolome, using the metabolomics approach.
Metabolomics is based on full analysis of metabolites in a bio-
logical sample using either mass spectrometry (MS) or nuclear
magnetic resonance (1H NMR) spectroscopy [11,12].
Being dynamic and highly sensitive to different environmental,
dietetic and disease stimuli, the metabolome is a perfect target for
diagnostic and prognostic approaches [13]. Identifying the meta-
bolic derangements that occur at the level of metabolome very
early in life will help detection of subsequent derangements
through regular follow-up. This should help future development
of therapeutic interventions or preventive strategies [14].
This study was designed to assess the metabolic fingerprints of
IUGR at birth in comparison to normal birth weight neonates, so
that we may share our results with the world-wide metabolomic
mapping system. Babies with recognized metabolic derangements
will be followed-up to detect onset of subsequent derangements
known to be associated with IUGR.2. Patients and methods
This case-control study was conducted in the Maternity Hospi-
tal; Ain Shams University, Cairo, Egypt, over a period of 13 months
from August 1, 2014 to August 31, 2015.
All SGA neonates, either term or preterm, born during the study
period were eligible. Samples from neonates with perinatal
asphyxia, intracranial hemorrhage, congenital malformations, or
congenital infections were discarded. Informed verbal consents
were obtained from parents or caregivers after explanation of the
study purpose and planning future visits.
Cord blood samples were collected in the delivery room, imme-
diately after cord clamping, from 40 SGA neonates and 20 gesta-
tional age-matched healthy, appropriate-for-gestational age
(AGA) neonates; as control. From each sample, three drops of blood
were put on a filter paper which was immediately analyzed or
stored at 80 C till analysis using Ultra Performance Liquid
Chromatography-Mass Spectrometry (UPLC-MS) [ACQUITY UPLC
M-Class System, Waters Corporation (NYSE:WAT), Milford, Mas-
sachusetts, USA].
Data management and Statistical analysis were done using SPSS
21 and MetaboAnalyst 2.0.
Data processing started with data integrity check, then missing
or zero values treatment, and data filtering. Data normalization
was done with the generalized log transformation. Data analysis
included Univariate analysis (T-test fold change) for preliminary
overview of potentially significant features, Correlation analysis,
and most importantly, Multivariate analysis including Principal
Components Analysis (PCA) and Partial Least Squares-
Discriminate Analysis (PLS-DA). Metabolite Set Enrichment Analy-
sis (MSEA) was used to identify meaningful patterns of compounds
combination, if any. Pathway analysis was based on KEGG meta-
bolic pathways as the backend knowledgebase.
In this study, we divided the several variables of metabolomic
profile into compounds for data reduction using PCA; this aimed
at summarization of data into much fewer variables called scores
which represent a weighted average of the original variables. The
weighting profiles are generally called loadings.
Loadings for any variable in PCA mean the importance of
this variable in that component (the higher the loading, the
higher is the importance of that variable to explain variability in
data).Then the components were subsequently compared with com-
ponents contained in the metabolite set library (KEGG).3. Results
The mean ± SD (min–max) gestational age of SGA neonates was
34 ± 2.4 (30–39) weeks. Their mean birth weight was 1320 ± 300
(800–2400) g, mean crown-heel length was 40 ± 2.6 (35–45) cm,
and mean head circumference was 28 ± 1.9 (25–32) cm. They were
18 (45%) males and 22 (55%) females. Eighty percent of them
(32/40) were delivered by Cesarean section and 75% (30/40) of
their mothers had preeclampsia.
Control group included 20 neonates with mean gestational age
of 35 ± 1.4 (32–38) weeks, mean birth weight of 3100 ± 400 (2100–
3800) g, mean crown-heel length of 48.5 ± 2.4 (45–51) cm, and
mean head circumference of 34.4 ± 1.2 (33–36) cm. They were 12
(60%) males and 8 (40%) females. They were all AGA and 18/20
(90%) of them were delivered vaginally.
The two groups were non-significantly different as regards ges-
tational age and sex distribution (p > 0.05), but cases had signifi-
cantly less birth weight, length and head circumference than
controls (p < 0.001).
Distinct metabolic profiles were identified for SGA neonates
that are different from AGA neonates. Important features identified
by t-tests are shown in Table 1. On the basis of individual metabo-
lites, PCA and PLS-DA revealed very high concentrations of acylcar-
nitines, especially C18-OH and C16-OH acylcarnitines, in cases
versus controls as well as significantly different levels – between
the two groups – of Histidine, Methionine, Arginine, Aspartic,
Valine, Alanine, Leucine, Isoleucine, Glutamic acid, Tyrosine,
Ornithine, Phenylalanine, and lastly citrulline.
Coefficients or VIP scores showed details of the variables which
were significantly higher or lower in IUGR compared to AGA neo-
nates. C18-OH, C16-OH acylcarnitines, for example, were of high-
est concentration in patients not controls, while Histidine and
Methionine were lower in patients than controls; Fig. 1.
Enrichment analysis showed disorders with highly significant
metabolomic similarity to IUGR profiles. Examples are some of
urea cycle defects such as Ornithine Transcarbamylase Deficiency
(OTC), N-acetylglutamate synthetase deficiency and Argininosuc-
cinic Aciduria, Lysinuric Protein Intolerance, Hyperornithinemia-
Hyperammonemia-Homocitrullinuria (HHH-Syndrome), tyrosine-
mia type I, autism, and diabetes mellitus (MODY); Table 2 and
Fig. 2.
Detailed results from pathway analysis are presented in Table 3.
It shows that the most significantly altered metabolic pathway in
IUGR neonates is the purine metabolism followed by thiamine
metabolism, primary bile acid biosynthesis, lysine degradation,
pyrimidine metabolism, and lastly glutathione metabolism, among
others.4. Discussion
Metabolomics provide a ‘‘snapshot” of metabolic status of a cell,
tissue, or organism in relation to genetic variations or external
stimuli [14]. During the last decade, many studies in neonates
focused on metabolic profiling in different disease states; in order
to establish maps for metabolic derangements in different
disorders.
In this study, we used UPLC-MS for measurement of amino
acids and acyl carnitine profiles in a group of SGA neonates in com-
parison to a matched group of AGA controls.
UPLC-MS provides significantly more resolution while reducing
run times; so it is rapid, simple, and improves sensitivity for the
analyses of many compounds [15].
Table 1
Important features identified by t-tests.
p value P value log(p value)
C18-OH 3.55E19 <0.001 18.45
Methionine 3.14E12 <0.001 11.503
Met:Phe 3.93E11 <0.001 10.406
Aspartic 5.02E11 <0.001 10.299
Histidine 1.04E10 <0.001 9.9834
C14-OH 1.24E08 <0.001 7.9071
C18:1 1.12E07 <0.001 6.9508
C4-Carnitine 1.44E07 <0.001 6.8413
C16-OH 2.34E07 <0.001 6.6317
C5-Carnitine 2.66E07 <0.001 6.575
C14:1 8.43E07 <0.001 6.0743
Phe: Tyr 2.54E06 <0.001 5.5955
C16:1 3.03E06 <0.001 5.5191
Valine 3.44E06 <0.001 5.4629
C4-DC (C5-OH) 5.82E06 <0.001 5.2353
Arginine 7.16E06 <0.001 5.1452
C18:1-OH 7.93E06 <0.001 5.1009
C14-Carnitine 2.78E05 <0.001 4.556
C6-Carnitine 3.90E05 <0.001 4.409
Glutamic acid 4.07E05 <0.001 4.3907
C10-1 0.000102 <0.001 3.9922
Tyrosine 0.000103 <0.001 3.9889
C12-Carnitine 0.000159 <0.001 3.7989
C4-OH (C3-DC) 0.000444 <0.001 3.353
C5-DC 0.000537 <0.001 3.27
C16-Carnitine 0.000776 <0.001 3.1104
C2-Carntine 0.000825 <0.001 3.0834
C10-Carnitine 0.000936 <0.001 3.0286
Leu-lle 0.001625 0.001 2.7892
C0-Carinitine 0.001705 0.001 2.7684
C18-Carnitine 0.002041 0.002 2.6902
C14:2 0.002059 0.002 2.6863
C8:1 0.002133 0.002 2.6709
C8-Carnitine 0.038071 0.038 1.4194
Alanine 0.040699 0.040 1.3904
C3 carnitine 0.043659 0.043 1.3599
Met = Methionine, Phe = Phenylalanine, Tyr = Tyrosine, Leu = Leucine,
Ile = Isoleucine.
Figure 1. Coefficients (VIP score). Red color = variable is high, green color = variable is low
patients not controls, while Histidine and Methionine were lower in patients than contr
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safe, and non-invasive, urine samples are preferred, especially in
very preterm babies [12,16].
Other biological fluids frequently used for metabolomic studies
in neonates include plasma, amniotic fluid, and cord blood, among
others [17–20].
We collected cord blood samples immediately after cord clamp-
ing and this absolutely does not affect the babies [21].
Several metabolites were identified, in our study, at different
concentrations allowing a clear discrimination between profiles
of SGA and AGA neonates at birth and supporting previous studies.
Certain amino acids and acyl carnitines were significantly
increased in cases than controls. Similar results in respect to some
amino acids; such as Alanine, Methionine, Ornithine, and Tyrosine,
were reported in a recent study in China [22].
Some studies as well using the metabolomic approach have
been published and all have shown altered metabolic profiles in
IUGR compared to AGA neonates [23,17,24].
Significant differences between the two groups in respect to
glucose and amino acid levels were previously identified in cord
blood analyzed using liquid chromatography high-resolution mass
spectrometry (LC-HRMS). Phenylalanine, tryptophan, and
methionine were particularly shown to be significantly different
and a cut-off value for the former two amino acids could be calcu-
lated for excellent discrimination between IUGR and AGA neonates
[25].
Phenylalanine and Tyrosine were also found to be significantly
elevated in our SGA compared to AGA neonates similar to several
studies, while the opposite was reported by Sanz Cortéz et al.
[21,26,27].
Sanz-Cortés et al. used 1H NMR spectroscopy rather than MS
and found reduced phenylalanine and tyrosine levels in IUGR
cases. They attributed this reduction to an altered placental trans-
port; possibly resulting from a ‘‘damaged” placental tissue,
together with the inherent hyper-catabolic state in IUGR [21].. It shows that C18-OH and C16-OH acylcarnitines were of highest concentration in
ols.
Table 2
Identified metabolomic disorders with significant similarity to SGA babies.
Total Hits Raw p Holm p
Ornithine Transcarbamylase Deficiency (OTC) 10 7 4.89E12 4.31E10
Glycine N-Methyltransferase Deficiency/Homocystinuria-Megaloblastic Anemia Due To Defect In Cobalamin Metabolism,
Cblg Complementation Type
1 1 5.86E09 4.86E07
Homocystinuria Due To Defect Of N(5,10)-Methylene Thf Deficiency/Homocystinuria (CBLE) 2 1 5.86E09 4.86E07
Methionine Adenosyl Transferase Deficiency/Methylmalonic Aciduria And Homocystinuria, Cblc Type/Methylmalonic Aciduria
And Homocystinuria, Cbld Type
2 1 5.86E09 4.86E07
Histidinemia 2 1 1.13E07 8.56E06
Dengue fever 3 2 1.32E07 9.92E06
Sotos Syndrome 2 2 2.17E06 0.000161
Argininosuccinic Aciduria (ASL) 6 3 2.59E06 0.000189
Short Bowel Syndrome (Under Arginine-Free Diet) 4 3 5.36E06 0.000381
Short-Bowel Syndrome (Permanent Intestinal Failure) 2 2 1.49E05 0.001028
Delta-Pyrrolidine-5-Carboxylate Synthase Deficiency 5 4 4.21E05 0.002649
3-Phosphoglycerate Dehydrogenase Deficiency 2 1 0.000136 0.008451
D-Glyceric Acidura/Hyperglycinemia, Non-Ketotic 1 1 0.000136 0.008451
Phosphoserine aminotransferase deficiency – new disorder? 2 1 0.000136 0.008451
Hypervalinemia 1 1 0.00024 0.012473
Congenital Glutamine Deficiency 1 1 0.000711 0.034825
Hyperinsulinism-Hyperammonemia Syndrome 2 1 0.000711 0.034825
Tyrosinemia II/Tyrosinemia III/Transient Tyrosinemia of Newborn 1 1 0.001806 0.084882
Carbamoyl Phosphate Synthetase Deficiency (CPS) 3 2 0.002188 0.094336
Lysinuric Protein Intolerance (LPI) 4 2 0.002753 0.11561
Hyperornithinemia With Gyrate Atrophy (HOGA) 4 2 0.002848 0.11677
Hyperornithinemia-Hyperammonemia-Homocitrullinuria [HHH-S] 3 2 0.002848 0.11677
Ethylmalonic Encephalopathy (EPEMA) 2 1 0.00463 0.17595
Lethal Infantile Cardiomyopathy: X-Linked Cardioskeletal Myopathy (Barth Syndrome) 1 1 0.00463 0.17595
Mamel (Methylmalonic Aciduria Mitochondrial Encephelopathy Leigh-Like) 2 1 0.00463 0.17595
Inflammatory Diseases 2 2 0.004854 0.17595
Myocardial Infarction 4 2 0.004854 0.17595
N-acetylglutamate synthetase deficiency. NAGS deficiency 5 3 0.006804 0.17595
Citrullinemia Type I 3 2 0.008398 0.17595
Citrullinemia Type II, Adult-Onset 2 1 0.17018 1
Narp Syndrome 1 1 0.17018 1
Hyperphenylalaniemia Due To Guanosine Triphosphate Cyclohydrolase Deficiency/Hyperphenylalaninemia Due
To 6-Pyruvoyltetrahydropterin Synthase Deficiency (Ptps)/Hyperphenylalaninemia Due To Dhpr-Deficiency/
Hyperphenylalaninemia Due To Pterin-4a-Carbinolamine Dehydratase/Phenylketonuria, Mother (MPKU)
1 1 0.47635 1
Dicarboxylic Aminoaciduria. Glutamate-Aspartate Transport Defect 2 1 0.65581 1
Hyperprolinemia, Type I 1 1 0.65581 1
Hyperprolinemia, Type II 2 2 0.68806 1
Total: total number of compounds in the pathway; Hits: the actually matched number from uploaded data; Raw p: original p value calculated from enrichment analysis; Holm
p: p value adjusted by Holm-Bonferroni method.
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be associated with adverse neurological outcome; being neuro-
transmitter precursors and this deserves further investigation [28].
Horgan et al. analyzed placenta villous explants from nine SGA
neonates using UPLC-MS and found that 574 metabolites were sig-
nificantly different from AGA controls. Changes in phospholipids
and essential amino acids (tryptophan, methionine, and phenylala-
nine) concentrations were, again, the most prominent [29].
Leucine and Valine were significantly elevated in our SGA neo-
nates. Theoretically, these amino acids are reduced during chronic
malnutrition and some research work on IUGR showed reduced
placental transport of leucine in these fetuses [30]. However, glu-
cocorticoids; which increase during stressful situations, reduce
the specific catabolic enzymes of these amino acids leading to sta-
tionary or even increased levels [31].
Interestingly, studies in adults could discriminate a population
who were extremely low birth weight (ELBW) infants from a con-
trol population of adults born at term with normal birth weight,
based on alterations in arginine and proline metabolism, in purine
and pyrimidine metabolism, in histidine beta-alanine metabolism,
and in the urea cycle [12].
Clear differences among the urinary metabolic profiles of AGA,
IUGR, and large-for-gestational-age (LGA) neonates; analyzed by
1H NMR spectroscopy, were also reported. The main metabolites
responsible for these differences were identified as myo-inositol,
creatinine, creatine, citrate, urea, and glycine. In particular, amongthese metabolites, myo-inositol was proposed as a potential bio-
marker of an altered glucose metabolism during fetal development
both in IUGR and LGA neonates [32].
Similar results regarding myo-inositol in urine and plasma of
IUGR neonates were reported in other studies using either 1H
NMR or gas chromatography-mass spectrometry (GC–MS)
[17,24,33].
So, increased myoinositol concentration in plasma and urine,
which has been associated with glucose intolerance and insulin
resistance, can be also considered as a valid marker of altered glu-
cose metabolism during fetal development in IUGR [34].
Glutamine levels in our study were significantly elevated in SGA
babies; a finding that was previously recorded [21,35].
Fetal glutamine is next to glucose as one of the main sources of
cellular energy during fetal life. It also plays a key role in fetal neu-
rodevelopment being a precursor of alpha amino butyric acid; a
neurotransmission inhibitor [36].
Increased glutamine levels in severe IUGR could be explained by
the inherent hypercatabolic status of IUGR in association to
decreased glucose levels. This lack of energy substrates may con-
vey to increase glutamine supply to the fetus through different
mechanisms; not only transfer from maternal blood, but also pla-
cental synthesis [35].
As for Acyl carnitine abnormalities found in our study, similar
abnormalities were previously described and attributed to either
chronic hypoxia or under-nutrition [37,38]. This seems to be con-
Figure 2. Enrichment analysis showing disorders with high metabolomic similarity to IUGR profiles.
Table 3
Detailed results from pathway analysis.
Total Hits Raw p Log (p) Holm adjust FDR p Impact
Aminoacyl-tRNA biosynthesis 75 9 5.49E17 37.441 1.54E15 1.54E15 0
Alanine, aspartate and glutamate metabolism 24 2 7.59E13 27.907 2.05E11 1.06E11 0.22982
Glycerophospholipid metabolism 39 1 9.76E12 25.353 2.54E10 9.11E11 0.00317
Nitrogen metabolism 39 5 4.54E10 21.514 1.13E08 3.18E09 0
Cysteine and methionine metabolism 56 1 5.86E09 18.956 1.41E07 3.28E08 0.03806
Histidine metabolism 44 1 1.13E07 16 2.59E06 4.50E07 0.13988
Beta-Alanine metabolism 28 1 1.13E07 16 2.59E06 4.50E07 0
Arginine and proline metabolism 77 5 8.82E06 11.639 0.000185 3.09E05 0.37816
D-Arginine and D-ornithine metabolism 8 2 2.77E05 10.492 0.000555 8.63E05 0
Purine metabolism 92 2 6.68E05 9.6139 0.001269 0.000187 0
Thiamine metabolism 24 2 9.32E05 9.281 0.001677 0.000237 0
Glycine, serine and threonine metabolism 48 1 0.000136 8.9006 0.002317 0.000239 0.18774
Primary bile acid biosynthesis 47 1 0.000136 8.9006 0.002317 0.000239 0.00822
Lysine degradation 47 1 0.000136 8.9006 0.002317 0.000239 0
Methane metabolism 34 1 0.000136 8.9006 0.002317 0.000239 0
Porphyrin and chlorophyll metabolism 104 1 0.000136 8.9006 0.002317 0.000239 0
Valine, leucine and isoleucine biosynthesis 27 1 0.00024 8.3354 0.002879 0.000336 0.01325
Valine, leucine and isoleucine degradation 40 1 0.00024 8.3354 0.002879 0.000336 0
Propanoate metabolism 35 1 0.00024 8.3354 0.002879 0.000336 0
Pantothenate and CoA biosynthesis 27 1 0.00024 8.3354 0.002879 0.000336 0
D-Glutamine and D-glutamate metabolism 11 1 0.000711 7.2492 0.005686 0.000905 0.02674
Pyrimidine metabolism 60 1 0.000711 7.2492 0.005686 0.000905 0
Tyrosine metabolism 76 1 0.001806 6.3166 0.010836 0.002107 0.04724
Ubiquinone and other terpenoid-quinone biosynthesis 36 1 0.001806 6.3166 0.010836 0.002107 0
Phenylalanine metabolism 45 2 0.004854 5.3279 0.019417 0.005228 0.11906
Phenylalanine, tyrosine and tryptophan biosynthesis 27 2 0.004854 5.3279 0.019417 0.005228 0.008
Glutathione metabolism 38 2 0.019292 3.948 0.038585 0.020007 0
Cyanoamino acid metabolism 16 2 0.063324 2.7595 0.063324 0.063324 0
Total: total number of compounds in the pathway; Hits: actually matched number from uploaded data; Raw p: original p value calculated from enrichment analysis; Holm p:
p value adjusted by Holm-Bonferroni method; FDR p: p value adjusted using False Discovery Rate; Impact: pathway impact value calculated from pathway topology analysis.
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rather than elevated, cord blood levels of acylcarnitines in smaller
babies, though the researchers also reported increased levels with
hypoxic insults [39].
Important to emphasize is that acylcarnitine analysis is used to
investigate commonmetabolic derangements such as insulin resis-
tance; as long-chain acylcarnitines interfere with insulin signaling
directly within the cell membrane [40].
Significant elevation of cord blood levels of lipids; mainly VLDL,
were also reported together with elevated creatine and glutamine
levels and reduced glucose, choline and phenylalanine in SGA com-
pared to AGA neonates [21].
In a recent review by Dessì and colleagues, they concluded that
intermediates of the tri carboxylic acid (TCA) cycle; such as glu-
tamine, alanine, leucine, and aspartate, are the most frequently
revealed metabolites in metabolomic studies in IUGR. Considering
the fact that insulin helps oxidation of acetyl-CoA and promotes
conversion of glucose to pyruvate through TCA cycle, insulin resis-
tance found pre- and post-natal in cases of IUGR may be responsi-
ble for these altered TCA intermediates [41].
Enrichment analysis in our study also revealed moderate simi-
larity of our IUGR neonates’ metabolic derangements to some dis-
orders like tyrosinemia type I, Neonatal Intrahepatic Cholestasis,
propionic acidemia and Maple syrup urine disease (MSUD) and
remote similarity to some other disorders as non-insulin depen-
dent diabetes mellitus, autism, and Very-Long-Chain Acyl Co-A
Dehydrogenase Deficiency (VLCAD). We speculate that the marked
deviation from normal metabolism which is found in IUGR causes
diversity of derangements which in turn are, individually, related
to a diversity of diseases. And although type II diabetes mellitus,
for instance, is a well known long-term morbidity strongly associ-
ated to IUGR, the definite metabolic derangements known in this
disease had a weak similarity to our studied neonates; denoting
that the previously shown similar derangements build up over
time and follow-up is thus strongly needed.
Promising treatment modalities are still under research, how-
ever, studies focusing on protein metabolism in IUGR neonates
suggested that both neonatal and long-term morbidity can be
modified by the rate of postnatal growth specifically during the
neonatal period [42].
We found that our IUGR neonates had their metabolic derange-
ments best matching those of urea cycle defects. This can be
explained by the previously shown impaired urea cycle function
in IUGR babies especially with more severe growth restriction,
and its postnatal maturation is delayed especially in preterm IUGR
ones [43,44]. However, intestinal urea recycling in these infants is
increased, which means that their protein usage is more efficient
[45].
So, when feeding these babies, protein intake must be balanced;
to be low enough to prevent accumulation of ammonia, but high
enough to guarantee adequate growth.5. Conclusion
In Summary, this study sheds light on the unique amino acid
and acyl carnitine profile of IUGR neonates at birth and can be used
to establish the metabolic map in these babies immediately at
birth to help defining cases that need further follow-up.Conflicts of interest
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